David Raben, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz

David Raben, University of Colorado Anschutz Medical Campus

Caption

David Raben, MD, and colleagues report promising phase 1 trial results of olaparib with cetuximab and radiation against heavy-smoker head and neck cancer.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.